SWOG S1612

Primary Category:

Treatment Protocols

Disease Category:

Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndrome



A Randomized Phase II/III Trial of “Novel Therapeutics” versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older


Effective 09/01/20, S1612 is permanently closed to accrual.

Effective immediately,10/25/18, and until further notice, patients will no longer receive nivolumab as part of this study. Additional details are provided in the Investigator Letter and Patient Information Letter.